492 related articles for article (PubMed ID: 36949429)
1. Development and validation of cuproptosis-related lncRNA signatures for prognosis prediction in colorectal cancer.
Pang L; Wang Q; Wang L; Hu Z; Yang C; Li Y; Wang Z; Li Y
BMC Med Genomics; 2023 Mar; 16(1):58. PubMed ID: 36949429
[TBL] [Abstract][Full Text] [Related]
2. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
[TBL] [Abstract][Full Text] [Related]
3. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
Zhang X; Ye Z; Xiao G; He T
Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
[TBL] [Abstract][Full Text] [Related]
4. A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer.
Wang L; Xiao K; Dong Z; Meng T; Cheng X; Xu Y
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10543-10559. PubMed ID: 37291405
[TBL] [Abstract][Full Text] [Related]
5. Development and Evaluation of a Novel Cuproptosis-Related lncRNA Signature for Gastric Cancer Prognosis.
Yin C; Gao M; Wang Q; Li H
Comput Math Methods Med; 2023; 2023():6354212. PubMed ID: 36820319
[TBL] [Abstract][Full Text] [Related]
6. A cuproptosis-related lncRNAs risk model to predict prognosis and guide immunotherapy for lung adenocarcinoma.
Li Q; Wang T; Zhu J; Zhang A; Wu A; Zhou Y; Shi J
Ann Transl Med; 2023 Mar; 11(5):198. PubMed ID: 37007546
[TBL] [Abstract][Full Text] [Related]
7. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma.
Liu B; Liu Z; Feng C; Li C; Zhang H; Li Z; Tu C; He S
Front Endocrinol (Lausanne); 2022; 13():987942. PubMed ID: 36313774
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of a novel cuproptosis-related lncRNA signature for predicting colorectal cancer patients' survival.
Liu F; Wu X
J Gastrointest Oncol; 2023 Apr; 14(2):650-662. PubMed ID: 37201038
[TBL] [Abstract][Full Text] [Related]
9. Cuproptosis-Related LncRNA Signature for Predicting Prognosis of Hepatocellular Carcinoma: A Comprehensive Analysis.
Chen Q; Sun T; Wang G; Zhang M; Zhu Y; Shi X; Ding Z
Dis Markers; 2022; 2022():3265212. PubMed ID: 36452343
[TBL] [Abstract][Full Text] [Related]
10. Developing four cuproptosis-related lncRNAs signature to predict prognosis and immune activity in ovarian cancer.
Liu L; Wang Q; Zhou JY; Zhang B
J Ovarian Res; 2023 Apr; 16(1):88. PubMed ID: 37122030
[TBL] [Abstract][Full Text] [Related]
11. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
12. Cuproptosis-related lncRNA signature for prognostic prediction in patients with acute myeloid leukemia.
Zhu Y; He J; Li Z; Yang W
BMC Bioinformatics; 2023 Feb; 24(1):37. PubMed ID: 36737692
[TBL] [Abstract][Full Text] [Related]
13. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
[TBL] [Abstract][Full Text] [Related]
14. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
Wang S; Bai H; Fei S; Miao B
Biochem Genet; 2023 Oct; ():. PubMed ID: 37898914
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
Pan Y; Zhang Q; Zhang H; Kong F
Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
[TBL] [Abstract][Full Text] [Related]
16. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
Front Immunol; 2022; 13():951455. PubMed ID: 36189298
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a novel 5 cuproptosis-related long noncoding RNA signature to predict diagnosis, prognosis, and drug therapy in clear cell renal cell carcinoma.
Chen Y; Hu W; Wei X; Zhang L; Shao Y; Tian J; Wang D; Wu B
Transl Androl Urol; 2023 Apr; 12(4):622-641. PubMed ID: 37181235
[TBL] [Abstract][Full Text] [Related]
18. In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma.
Wang Y; Huang X; Chen S; Jiang H; Rao H; Lu L; Wen F; Pei J
Curr Oncol; 2022 Sep; 29(9):6573-6593. PubMed ID: 36135086
[TBL] [Abstract][Full Text] [Related]
19. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
Liu Y; Jiang J
Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
[TBL] [Abstract][Full Text] [Related]
20. Identification of cuproptosis-related lncRNA for predicting prognosis and immunotherapeutic response in cervical cancer.
Kong X; Xiong Y; Xue M; He J; Lu Q; Chen M; Li L
Sci Rep; 2023 Jul; 13(1):10697. PubMed ID: 37400520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
